| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2012-12-11 | Warnex's Bioanalytical Services division | Biotrial Research (France) | C$ 6 million (€4.65 million) and additional payment | services |
| 2012-12-10 | deCODE Genetics (Iceland) | Amgen (USA) | $415 million (€320.8 million) | Genomics |
| 2012-12-04 | Gambro (Sweden) | Baxter (USA - IL) | 26.5 billion SEK (approximately $4.0 billion - € 3 billion) | dialysis products |
| 2012-11-07 | Epicept (USA) | Immune Pharmaceuticals (Israel) | drug development |
|
| 2012-11-06 | Ingen Biosciences (France) | Exonhit (France) | €18 million | diagnostics |
| 2012-10-22 | Octoplus (The Netherlands) | Dr Reddy's (India) | € 27.39 million | services |
| 2012-10-15 | Amdipharm (UK) | Cinven (UK) | £ 367 million (€ 451.5 million) | drug industry |
| 2012-10-08 | Diamyd Inc (US subsidiary of Diamyd Medical - Sweden) | Periphagen Holdings (USA) | The purchase price amounts to one dollar and shares in the acquiring company, providing Diamyd Medical a holding of 10 percent in Periphagen Holdings, Inc. In addition, Diamyd Medical may receive up to USD 10 million, primarily in milestone payments, as well as 10 percent of upfront payments and other payments Periphagen Holdings, Inc. may receive from future partners, and royalties on future sales of NTDDS based drugs. | Gene therapy |
| 2012-10-01 | PX'Therapeutics (France) | Aguettant (France) | undisclosed | Manufacturing |
| 2012-09-19 | Bluegnome (UK) | Illumina (USA) | undisclosed | diagnostic |
| 2012-09-18 | Cangene Plasma Resources' U.S. based plasma centres | Grifolds (Spain) | undisclosed | Plasma |
| 2012-09-10 | Vitalea Science (USA) | Eckert & Ziegler (Germany) Vitalea Science (USA) | undisclosed | bioanalytical CRO |
| 2012-08-29 | JSW Life Sciences (Austria) | QPS (USA) | undisclosed | CRO |
| 2012-08-23 | Farma-Projekt (Poland) | Recordati (Italy) | PLN 71.0 million (€16.9 million) | cardiovascular diseases |
| 2012-08-22 | Biochrom (Germany) | Merck KGaA (Germany) | undisclosed | cell culture |
| 2012-08-21 | RIEMSER Arzneimittel (Germany) | AXA Private Equity (France) | pharmaceutical industry |
|
| 2012-08-17 | Mercury Pharma (UK) | Cinven (UK) | £465 million (€ 591.6 million) | specialty pharmaceuticals |
| 2012-08-03 | Human Genome Sciences (USA) | GSK (UK) | $3.6 billion (€2.9 billion) | Oncology |
| 2012-07-20 | Fenwal Holdings (USA) | Fresenius Kabi (Germany) | undisclosed | Transfusion medicine |
| 2012-07-18 | stake in Accera (USA) | Nestle Health Sciences (Switzerland) | undisclosed | Nutrition |
